Remedium Lifecare Past Earnings Performance
Past criteria checks 6/6
Remedium Lifecare has been growing earnings at an average annual rate of 82.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 72.3% per year. Remedium Lifecare's return on equity is 238.7%, and it has net margins of 1.9%.
Key information
82.6%
Earnings growth rate
68.2%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 72.3% |
Return on equity | 238.7% |
Net Margin | 1.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Remedium Lifecare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 27,254 | 528 | 16 | 0 |
30 Sep 23 | 10,536 | 85 | 18 | 0 |
30 Jun 23 | 8,121 | 48 | 17 | 0 |
31 Mar 23 | 5,098 | 54 | 16 | 0 |
31 Dec 22 | 4,761 | 90 | 14 | 0 |
30 Sep 22 | 5,057 | 82 | 12 | 0 |
30 Jun 22 | 4,660 | 71 | 6 | 0 |
31 Mar 22 | 5,048 | 11 | 11 | 0 |
31 Dec 21 | 5,204 | 25 | 9 | 0 |
30 Sep 21 | 3,278 | 20 | 7 | 0 |
30 Jun 21 | 2,279 | 9 | 2 | 0 |
31 Mar 21 | 900 | 5 | 6 | 0 |
31 Dec 20 | 349 | 5 | 6 | 0 |
30 Sep 20 | 221 | 3 | 2 | 0 |
30 Jun 20 | 29 | 3 | 2 | 0 |
31 Mar 20 | 29 | 3 | 5 | 0 |
31 Dec 19 | 23 | 0 | 1 | 0 |
30 Jun 19 | 3 | 0 | 0 | 0 |
31 Mar 19 | 2 | 0 | 0 | 0 |
31 Dec 18 | 2 | 0 | 1 | 0 |
30 Jun 18 | 3 | 1 | 2 | 0 |
31 Mar 18 | 4 | 0 | 1 | 0 |
31 Dec 17 | 9 | 0 | 1 | 0 |
30 Sep 17 | 9 | 0 | 1 | 0 |
30 Jun 17 | 11 | 0 | 1 | 0 |
31 Mar 17 | 13 | 0 | 1 | 0 |
31 Dec 16 | 27 | 0 | 2 | 0 |
30 Sep 16 | 39 | 0 | 2 | 0 |
30 Jun 16 | 40 | 0 | 1 | 0 |
31 Mar 16 | 39 | 0 | 1 | 0 |
31 Dec 15 | 22 | 0 | 1 | 0 |
30 Sep 15 | 12 | 0 | 1 | 0 |
30 Jun 15 | 16 | 3 | 1 | 0 |
31 Mar 15 | 21 | 6 | 1 | 0 |
31 Mar 14 | 26 | 0 | 1 | 0 |
Quality Earnings: 539561 has high quality earnings.
Growing Profit Margin: 539561's current net profit margins (1.9%) are higher than last year (1.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539561's earnings have grown significantly by 82.6% per year over the past 5 years.
Accelerating Growth: 539561's earnings growth over the past year (483.9%) exceeds its 5-year average (82.6% per year).
Earnings vs Industry: 539561 earnings growth over the past year (483.9%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 539561's Return on Equity (238.7%) is considered outstanding.